See more : GTN Limited (GTNLF) Income Statement Analysis – Financial Results
Complete financial analysis of Eisai Co., Ltd. (ESALY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eisai Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- MDM Group, Inc. (MDDM) Income Statement Analysis – Financial Results
- LANXESS Aktiengesellschaft (LXS.DE) Income Statement Analysis – Financial Results
- Rio Paranapanema Energia S.A. (GEPA3.SA) Income Statement Analysis – Financial Results
- PT Surya Fajar Capital Tbk (SFAN.JK) Income Statement Analysis – Financial Results
- Adacel Technologies Limited (ADA.AX) Income Statement Analysis – Financial Results
Eisai Co., Ltd. (ESALY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.eisai.co.jp
About Eisai Co., Ltd.
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 756.23B | 645.94B | 695.62B | 642.83B | 600.05B | 539.10B | 547.92B | 548.47B | 600.35B | 573.68B | 647.93B | 768.93B | 803.14B | 781.71B | 734.42B | 674.18B | 601.26B | 533.14B | 500.13B | 466.61B | 431.75B | 361.71B | 302.47B |
| Cost of Revenue | 174.83B | 161.31B | 175.69B | 184.49B | 201.25B | 195.91B | 194.46B | 193.60B | 188.16B | 174.11B | 173.35B | 167.78B | 160.73B | 152.41B | 118.94B | 109.37B | 104.51B | 98.61B | 97.18B | 102.47B | 101.57B | 98.60B | 91.68B |
| Gross Profit | 581.40B | 484.63B | 519.93B | 458.34B | 398.80B | 343.19B | 353.46B | 354.87B | 412.20B | 399.57B | 474.57B | 601.15B | 642.41B | 629.29B | 615.48B | 564.81B | 496.75B | 434.53B | 402.95B | 364.15B | 330.18B | 263.11B | 210.79B |
| Gross Profit Ratio | 76.88% | 75.03% | 74.74% | 71.30% | 66.46% | 63.66% | 64.51% | 64.70% | 68.66% | 69.65% | 73.24% | 78.18% | 79.99% | 80.50% | 83.81% | 83.78% | 82.62% | 81.50% | 80.57% | 78.04% | 76.47% | 72.74% | 69.69% |
| Research & Development | 171.74B | 150.30B | 140.12B | 144.84B | 139.58B | 112.48B | 122.31B | 131.91B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 225.43B | 108.30B | 93.25B | 78.33B | 69.02B | 59.70B | 55.04B | 49.61B | 46.70B |
| General & Administrative | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Other Expenses | -10.52B | 1.17B | -1.99B | -866.00M | -1.85B | -8.03B | -13.60B | 80.00M | 341.09B | 329.10B | 378.82B | 488.03B | 556.00B | 537.48B | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 0.00 | -130.00M | -96.00M |
| Operating Expenses | 527.65B | 432.87B | 394.43B | 372.19B | 321.59B | 284.13B | 301.53B | 326.53B | 341.09B | 329.10B | 378.82B | 488.03B | 556.00B | 537.48B | 597.73B | 459.55B | 401.04B | 347.72B | 319.88B | 288.15B | 257.49B | 204.14B | 173.66B |
| Cost & Expenses | 702.48B | 594.18B | 570.12B | 556.68B | 522.84B | 480.03B | 495.99B | 520.13B | 529.25B | 503.21B | 552.17B | 655.81B | 716.73B | 689.90B | 716.67B | 568.91B | 505.55B | 446.33B | 417.06B | 390.62B | 359.06B | 302.75B | 265.34B |
| Interest Income | 2.40B | 2.15B | 4.02B | 4.86B | 2.56B | 1.85B | 2.02B | 2.43B | 963.00M | 1.12B | 815.00M | 997.00M | 1.25B | 3.17B | 5.33B | 5.12B | 3.35B | 1.70B | 1.34B | 1.47B | 2.78B | 0.00 | 0.00 |
| Interest Expense | 1.69B | 1.36B | 1.46B | 1.56B | 2.97B | 3.24B | 3.49B | 4.89B | 5.55B | 6.69B | 6.89B | 7.42B | 7.66B | 7.63B | 762.00M | 65.00M | 79.00M | 52.00M | 28.00M | 56.00M | 296.00M | 687.00M | 1.13B |
| Depreciation & Amortization | 38.40B | 36.30B | 33.70B | 26.84B | 26.18B | 26.48B | 34.06B | 38.94B | 48.52B | 51.09B | 48.69B | 51.26B | 57.37B | 58.63B | 34.40B | 26.80B | 24.99B | 22.45B | 18.49B | 15.33B | 15.33B | 15.00B | 15.14B |
| EBITDA | 96.79B | 89.85B | 162.53B | 114.76B | 103.37B | 84.51B | 87.91B | 69.51B | 112.05B | 128.94B | 149.81B | 160.86B | 138.78B | 136.08B | 55.34B | 136.68B | 120.71B | 109.80B | 101.59B | 27.81B | 78.52B | 58.65B | 13.34B |
| EBITDA Ratio | 12.80% | 13.91% | 23.36% | 17.85% | 17.23% | 15.68% | 16.04% | 12.67% | 18.66% | 22.48% | 23.12% | 20.92% | 17.28% | 17.41% | 7.53% | 20.27% | 20.08% | 20.60% | 20.31% | 5.96% | 18.19% | 16.21% | 4.41% |
| Operating Income | 58.39B | 51.77B | 125.50B | 86.15B | 77.21B | 59.06B | 51.94B | 28.34B | 71.11B | 70.46B | 95.75B | 113.12B | 86.41B | 91.81B | 17.75B | 105.26B | 95.70B | 86.81B | 83.06B | 75.86B | 72.69B | 58.97B | 37.13B |
| Operating Income Ratio | 7.72% | 8.01% | 18.04% | 13.40% | 12.87% | 10.96% | 9.48% | 5.17% | 11.84% | 12.28% | 14.78% | 14.71% | 10.76% | 11.74% | 2.42% | 15.61% | 15.92% | 16.28% | 16.61% | 16.26% | 16.84% | 16.30% | 12.28% |
| Total Other Income/Expenses | -3.93B | 785.00M | 2.56B | 3.30B | -409.00M | -1.40B | -1.46B | -2.46B | -12.89B | 966.00M | -1.10B | -10.55B | -12.13B | -21.32B | -96.00M | 5.07B | 378.00M | 845.00M | -539.00M | -6.04B | -9.93B | -16.13B | -11.60B |
| Income Before Tax | 54.46B | 52.55B | 128.06B | 89.45B | 76.80B | 57.67B | 50.47B | 25.88B | 58.21B | 71.43B | 94.65B | 102.57B | 74.28B | 70.48B | 17.65B | 110.33B | 96.08B | 87.65B | 82.52B | 69.83B | 62.75B | 42.84B | 25.54B |
| Income Before Tax Ratio | 7.20% | 8.14% | 18.41% | 13.92% | 12.80% | 10.70% | 9.21% | 4.72% | 9.70% | 12.45% | 14.61% | 13.34% | 9.25% | 9.02% | 2.40% | 16.37% | 15.98% | 16.44% | 16.50% | 14.96% | 14.53% | 11.84% | 8.44% |
| Income Tax Expense | 8.74B | 10.07B | 5.60B | 22.97B | 22.38B | 15.42B | -4.57B | -17.58B | 25.03B | 22.88B | 35.71B | 34.79B | 33.41B | 22.13B | 37.19B | 39.20B | 32.23B | 31.80B | 32.93B | -28.61B | 26.10B | 19.63B | -14.20B |
| Net Income | 45.72B | 42.12B | 121.77B | 63.39B | 51.85B | 39.36B | 54.93B | 43.25B | 32.96B | 48.28B | 58.51B | 67.39B | 40.34B | 47.68B | -17.01B | 70.61B | 63.41B | 55.51B | 50.15B | 41.03B | 36.80B | 23.32B | 11.28B |
| Net Income Ratio | 6.05% | 6.52% | 17.50% | 9.86% | 8.64% | 7.30% | 10.03% | 7.89% | 5.49% | 8.42% | 9.03% | 8.76% | 5.02% | 6.10% | -2.32% | 10.47% | 10.55% | 10.41% | 10.03% | 8.79% | 8.52% | 6.45% | 3.73% |
| EPS | 159.44 | 146.94 | 424.77 | 221.12 | 180.97 | 137.63 | 192.50 | 151.67 | 115.56 | 169.38 | 205.33 | 236.52 | 141.58 | 167.35 | -59.80 | 238.10 | 221.81 | 194.22 | 174.26 | 138.34 | 126.14 | 78.67 | 38.03 |
| EPS Diluted | 159.44 | 146.94 | 424.77 | 221.12 | 180.97 | 137.42 | 192.25 | 151.53 | 115.46 | 169.31 | 205.31 | 236.51 | 141.56 | 167.30 | -59.80 | 238.10 | 221.81 | 194.22 | 174.26 | 138.34 | 126.14 | 78.67 | 38.03 |
| Weighted Avg Shares Out | 286.73M | 286.65M | 286.66M | 286.66M | 286.48M | 285.98M | 285.37M | 285.17M | 285.17M | 285.01M | 284.97M | 284.94M | 284.91M | 284.90M | 284.49M | 296.57M | 285.87M | 285.79M | 287.78M | 296.57M | 291.72M | 296.45M | 296.45M |
| Weighted Avg Shares Out (Dil) | 286.73M | 286.65M | 286.66M | 286.66M | 286.48M | 286.42M | 285.75M | 285.44M | 285.42M | 285.13M | 284.99M | 284.95M | 284.95M | 284.99M | 284.49M | 296.57M | 285.87M | 285.79M | 287.78M | 296.57M | 291.72M | 296.45M | 296.45M |
Biogen and Eisai say EU regulatory committee adopted negative opinion for its Alzheimer's treatment
Biogen Inc. BIIB, -0.15% and partner Eisai Co. Ltd ESALY, +1.13% 4523, -2.11% said Friday an advisory committee to the European Medicines Agency has adopted a negative opinion on its Alzheimer's treatment aducanumab, known as aduhelm in the U.S. The...
Update on Regulatory Submission for Aducanumab in the European Union
Biogen to seek re-examination following CHMP negative opinion for aducanumab Biogen to seek re-examination following CHMP negative opinion for aducanumab
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
The European Commission has approved a combination of Merck & Co Inc's (NYSE: MRK) Keytruda plus Eisai Co Ltd's (OTC: ESALY) Lenvima for advanced or recurrent endometrial carcinoma. The approval covers adult patients who have disease progression on or following prior treatment with a platinum‑containing therapy...
Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference
TOKYO and CAMBRIDGE, Mass., Nov. 11, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today results of sensitivity analyses evaluating the consistency...
Eisai Co., Ltd. (ESALF) CEO Haruo Naito on Q2 2022 Results - Earnings Call Transcript
Eisai Co., Ltd. (ESALF) CEO Haruo Naito on Q2 2022 Results - Earnings Call Transcript
Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug
Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab is an anti-amyloid beta (Aβ) protofibril antibody.
Eisai Co., Ltd. (ESALF) Management on Q1 2022 Results - Earnings Call Transcript
Eisai Co., Ltd. (ESALF) Management on Q1 2022 Results - Earnings Call Transcript
Biogen - Eisai Launch 5-Year Study To See How Well Alzheimer's Drug Aduhelm Works In Real World
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) launched a real-world, Phase 4 study to evaluate the long-term effects of the Aduhelm (aducanumab-avwa) 100 mg/mL solution for injection this time, with a focus on recruiting more patients from minority groups. The companies are...
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) showed the treatment slowed cognitive, functional, and behavioral decline in the early stages of the disease. Treatment effects were exhibited across all...
Eisai Alzheimer's Disease Pipeline Research, Including New Lecanemab (BAN2401) Data, to be Presented at 2021 Alzheimer's Association International Conference (AAIC)
WOODCLIFF LAKE, N.J., July 22, 2021 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd.
Source: https://incomestatements.info
Category: Stock Reports